{"id":13572,"date":"2022-01-25t16:33:52","date_gmt":"2022-01-25t16:33:52","guid":{"rendered":"\/\/www.aselpijama.com\/?p=13572"},"modified":"2024-08-19t10:01:30","modified_gmt":"2024-08-19t09:01:30","slug":"people-with-underlying-health-conditions-urged-to-sign-up-to-covid-19-antiviral-study","status":"publish","type":"post","link":"\/\/www.aselpijama.com\/people-with-underlying-health-conditions-urged-to-sign-up-to-covid-19-antiviral-study\/","title":{"rendered":"people with underlying health conditions urged to sign up to covid-19 antiviral study"},"content":{"rendered":"
adults over the age of 50 or with an underlying health condition who test positive for covid-19 are being urged to sign up for a world-first study into life-saving antiviral treatments.<\/p>
at least 6,000 more participants are needed for the cutting-edge treatments through the panoramic<\/a> study. <\/p> this is so that expert scientists can understand more about how to deploy these treatments in the nhs more widely later in the year \u2013 including who would benefit most from receiving antiviral treatments for covid-19.<\/p> antivirals are medicines which can be swallowed as a tablet to help treat people with covid-19 infections to reduce the risk of hospitalisations and death. molnupiravir, which is currently being deployed through the study, has shown to reduce this for at risk, non-hospitalised adults with mild to moderate covid-19 by 30% – potentially saving thousands of lives once the drugs are available to the nhs.<\/p> anyone over the age of 50 or between 18 to 49 with an underlying health condition can sign up to the study<\/a> as soon as they receive a positive pcr or lateral flow test result. they need to be experiencing covid-19 symptoms that began in the last five days to be eligible to enrol.<\/p> the uk-wide study, run by the university of oxford and launched at the start of december 2021, currently has around 4,500 trial participants signed up, but needs thousands more to sign up as soon as possible to gather the data necessary. this will ensure medical experts can learn more about the potential benefits these treatments bring to vaccinated patients, and will help the nhs to develop plans for rolling out the antivirals to further patients later this year.<\/p>